Nautilus Biotechnology Inc expected to post a loss of 17 cents a share - Earnings Preview

Nautilus Biotechnology

27/10/2023 19:35

* Nautilus Biotechnology Inc  NAUT.OQ   NAUT.O  is expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Nautilus
Biotechnology
Inc is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nautilus
Biotechnology Inc is $6​, above​ its last closing price
of $2.51. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3
 Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28
 Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3​
 Sep. 30 2022  -0.15       -0.15      -0.11     Beat    25.4
 ​​Jun.        -0.17       -0.17      -0.12     Beat    28.4
 30 2022                                                
 Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17​
 Dec. 31 2021  -0.14       -0.13      -0.13     Met     1.9
 Sep. 30 2021  -0.10       -0.10      -0.12     Missed  -20
 This summary was machine generated October 27 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated